Radiopharm Theranostics (Radiopharm Theranostics) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Radiopharm Theranostics's annualized Gross Profit for the quarter that ended in Dec. 2023 was $0.00 Mil. Radiopharm Theranostics's average Total Assets over the quarter that ended in Dec. 2023 was $46.33 Mil. Therefore, Radiopharm Theranostics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.

Radiopharm Theranostics Gross-Profit-to-Asset % Historical Data

The historical data trend for Radiopharm Theranostics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Gross-Profit-to-Asset % Chart

Radiopharm Theranostics Annual Data

Trend

Jun22

Jun23

Gross-Profit-to-Asset %

0.01

0.36

Radiopharm Theranostics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	-	-	0.68	-	-

Competitive Comparison of Radiopharm Theranostics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Radiopharm Theranostics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radiopharm Theranostics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Gross-Profit-to-Asset % falls into.

Radiopharm Theranostics Gross-Profit-to-Asset % Calculation

Radiopharm Theranostics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2023 )	/	( (Total Assets (A: Jun. 2022 )	+	Total Assets (A: Jun. 2023 ))	/ count )
	=	0.196	/	( (58.595	+	50.302)	/ 2 )
	=	0.196	/	54.4485
	=	0.36 %

Radiopharm Theranostics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0	/	( (50.302	+	42.365)	/ 2 )
	=	0	/	46.3335
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Radiopharm Theranostics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Radiopharm Theranostics (Radiopharm Theranostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

RAD:Australia

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.radiopharmtheranostics.com

Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (Radiopharm Theranostics) Headlines

From GuruFocus

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-20-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 07-10-2022

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire • 10-19-2022

RADIOPHARM ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND ASSUMES PD-L1 LICENSING AGREEMENT FROM NANOMAB

By PRNewswire PRNewswire • 08-04-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-30-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-10-2022